Results 271 to 280 of about 40,773 (330)

Correction to “The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia” [PDF]

, 2015
Norman E. Lepor, Laurn Contreras, Chirag S. Desai, Dean J. Kereiakes   +3 more
openalex   +1 more source

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy. [PDF]

Sci Rep
Thaiprayoon A, Chantarasorn Y, Oonanant W, Kasorn A, Longsompurana P, Tapaneeyakorn S, Riangrungroj P, Loison F, Kruse AC, DeLisa MP, Waraho-Zhmayev D.   +10 more
europepmc   +1 more source

Remnant cholesterol concentrations best explain the cardiovascular benefit of APOC3 genetic inhibition: a drug target Mendelian randomization study. [PDF]

Eur Heart J Open
Gagnon E, Gill D, Burgess S, Arsenault BJ.   +3 more
europepmc   +1 more source

Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects

, 2014
Gilles Lambert, Francine Petrides, Mathias Chatelais, Dirk Blom, Benjamin Choque, Fatiha Tabet, Gida Wong, Kerry‐Anne Rye, Amanda J. Hooper, John R. Burnett, Philip J. Barter, A. David Marais   +11 more
openalex   +1 more source

Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. [PDF]

Cardiovasc Diabetol
Rossi A, Masi D, Zilich R, Baccetti F, Baronti W, Falcetta P, Morviducci L, Musacchio N, Muselli M, Ozzello A, Salomone E, Verda D, Vezenkova M, Candido R, Ponzani P.   +14 more
europepmc   +1 more source

Targeting lipoprotein(a): Pharmacotherapy in focus. [PDF]

Eur Heart J Cardiovasc Pharmacother
Tan DS, Ooi ZH, Lew CSF.
europepmc   +1 more source

PCSK9: A key factor modulating atherosclerosis

, 2014
Sha Li, Jian‐Jun Li
openalex   +2 more sources

Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers. [PDF]

Lipids Health Dis
Jin P, Ma J, Wu P, Bian Y, Ma X, Jia S, Zheng Q.   +6 more
europepmc   +1 more source

Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study. [PDF]

Eur Heart J Cardiovasc Pharmacother
Ciofani JL, Han D, Rao K, Gill D, Woolf B, Rahimi K, Allahwala UK, Bhindi R.   +7 more
europepmc   +1 more source

Evaluating the role of PCSK9 inhibitors in reducing cardiovascular events among statin-intolerant patients: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Farhan M, Hussein GA, Alom T, Das A, Durrani TA, Hayani ZM, Alkassar A, Oweis HA, Nazir MH, Dhillon DK, Servil E, Patel T.   +11 more
europepmc   +1 more source